Comparison of Participants Who Received a CanGaroo® Envelope, TYRX™ Envelope, or no Envelope During CIED Implantation

Cardiac Disease Clinical Trial

— HEAL  

Official title:

A Multi-Center Study Evaluating Participants Who Received CanGaroo® Envelope, TYRX™ Envelope, or No Envelope During CIED Implantation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04645173
• Other study ID #: CPR-2214
• Status: Completed
• Start date: February 2, 2021
• Est. completion date: December 31, 2023

Study information

• Verified date: January 2024
• Source: Aziyo Biologics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objective of this study is to gather information on participants returning at time of CIED change-out or revision who underwent a device implantation with either a CanGaroo® envelope, TYRX™ envelope, or no envelope.

Description:

This multi-center study will enroll up to approximately 100 participants who have undergone one or more implantations of a CIED with either CanGaroo®, TYRX™, or no envelope (up to approximately 30-35 participants per cohort) and are returning for a CIED change-out or revision procedure at least 4 months or longer from their prior procedure.

Once enrolled, each participant will have their medical history data collected (baseline demographics, medical history, prior CIED exchanges/revisions, and post implant clinical events). Prior to the scheduled change-out/revision procedure, there will be an assessment of the current healed implant site skin incision independently by both the participant and investigator using the Patient and Observer Scar Assessment Scale (POSAS), as well as photographs taken of the current skin scar.

During the change-out/revision procedure, additional investigator assessments will include photographic documentation of CIED implant pocket lining, classification of the extent of lead adhesions in the implant pocket, and biopsies of the anterior and posterior capsule walls for histologic analysis. Procedural details and any complications/AEs that occur during the change-out/revision procedure will also be captured.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: December 31, 2023
• Est. primary completion date: October 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Participants who previously underwent one or more prior CIED implantations utilizing a CanGaroo® envelope, TYRX™ envelope, or no envelope and are returning for a CIED change-out or revision procedure at least 4 months or longer from their prior procedure.

2. The following possible scenarios would be eligible for enrollment:

a. One prior CIED Implant: i. No envelope ii. CanGaroo® envelope iii. TYRX™ envelope b. Multiple prior CIED Implants (envelope type should remain the same for each participant throughout their implant history): i. No envelope ? no envelope ii. No envelope ? CanGaroo® envelope iii. No envelope ? TYRX™ envelope iv. CanGaroo® envelope ? CanGaroo® envelope v. TYRX™ envelope ? TYRX™ envelope vi. No envelope ? CanGaroo® envelope ? CanGaroo® envelope vii. No envelope ? no envelope ? CanGaroo® envelope viii. No envelope ? TYRX™ envelope ? TYRX™ envelope ix. No envelope ? no envelope ? TYRX™ envelope

3. Participants aged 18 years or older at time of enrollment.

4. Participant is able and agrees to provide written informed consent and use of PHI.

5. Participants for whom prior CIED implant history information can be obtained.

Exclusion Criteria:

1. Active infection involving the CIED implant site (clinical diagnosis of an active infection at the time of change-out/revision procedure).

2. Participants under the age of 18 at time of enrollment.

3. Participants with a history of multiple prior CIED implants over time using more than one type of envelope will be excluded as well as participants with a history of one type of envelope use, but the current pocket does not have an envelope. Scenarios that would be excluded:

1. CanGaroo® envelope ? TYRX™ envelope

2. TYRX™ envelope ? CanGaroo® envelope

3. CanGaroo® envelope - no envelope

4. TYRX™ envelope ? no envelope

5. No envelope ? CanGaroo® envelope ? no envelope

6. No envelope ? TYRX™ envelope ? no envelope

7. No envelope ? CanGaroo® envelope ? TYRX™ envelope

8. No envelope ? TYRX™ envelope ? CanGaroo® envelope

9. CanGaroo® envelope ? no envelope ? TYRX™ envelope

10. TYRX™ envelope ? no envelope ? CanGaroo® envelope

11. CanGaroo® envelope ? TYRX™ envelope ? no envelope

12. TYRX™ envelope ? CanGaroo® envelope ? no envelope

13. CanGaroo® envelope ? CanGaroo® envelope ? no envelope

14. TYRX™ envelope ? TYRX™ envelope ? no envelope

4. Participants undergoing a change-out or revision procedure less than 4 months from their prior procedure.

Related Conditions & MeSH terms

• Cardiac Disease
• Heart Diseases

Intervention

Device:
• CIED envelope
Evaluation of the difference in cohorts for soft tissue healing surrounding the CIED implant and clinical outcomes and complications.

Locations

Country	Name	City	State
United States	Bay Pines VA	Bay Pines	Florida
United States	Valley Heart Rhythm Specialists	Chandler	Arizona
United States	University of Virginia Medical Center	Charlottesville	Virginia
United States	Atrium Health	Concord	North Carolina
United States	East Carolina University/Vidant Medical Center	Greenville	North Carolina
United States	Baptist Medical Center	Jacksonville	Florida
United States	University of Florida	Jacksonville	Florida
United States	U of L Health/Jewish Hospital	Louisville	Kentucky
United States	Columbia University Irving Medical Center	New York	New York
United States	Penn Presbyterian Medical Center	Philadelphia	Pennsylvania
United States	Prairie Education & Research Cooperative / St. John's Hospital	Springfield	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Aziyo Biologics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Patient and Observer Scar Assessment Scale (POSAS)	10-point score: Each item of the POSAS is rated on a 10-point score. The lowest score is '1', which corresponds to the situation of normal skin (i.e., normal pigmentation, no itching). Score 10 equals the largest difference from normal skin (i.e., the worst imaginable scar or sensation).; Total score: The total score of both scales can be simply calculated by summing up the scores of each of the six items. The total score can range from 6 to 60. The overall opinion item is not included in the sum score.	Pre-Surgery Visit
Other	CIED Scar Photographs	Comparison of photographs of the previous skin incision scar taken pre-surgery. The visual differences in the skin incision scar appearance between the 3 cohorts may correlate with histologic findings and/or post-implant clinical outcomes or events.	Pre-Surgery Visit
Other	CIED Implant Photographs	Comparison of photographs of the previous CIED implant pocket interior taken intraoperatively. The visual differences in interior capsule wall appearance between the 3 cohorts may correlate with histologic findings and/or post-implant clinical outcomes or events.	Surgical Procedure Visit
Other	Assessment of Lead Adhesions within the Implant Pocket	This observation should be made while the CIED device is mobilized and removed from within the implant pocket.; The classification system is based on two estimated factors: The amount of fibrosis by visual estimate (none/trivial, mild, moderate, or severe).; NOTE: If calcification is present, the capsule should be classified as Class 3 (severe).; The estimate of the percentage of the lead coiled within the implant pocket that is adhered or trapped within the capsule wall (Class 0: none, Class 1: <30%, Class 2: 30%-60%, and Class 3: >60%).	Surgical Procedure Visit
Primary	Blinded Histologic Evaluation of Biopsies Taken from the Anterior and Posterior Capsule Wall	Microscopic analysis of cellularity, vascularity, collagen density, necrosis, infectious agents, remnant device material, giant cells, and fibrotic capsule thickness will be evaluated for each biopsy site using a quantitative scoring system with an attempt to distinguish between remnant envelope collagen (if ECM envelope was used) and neocollagen from the participant. Composite (total) and average scores will be determined based on the individual scores from each biopsy site. The quantitative thickness of each fibrotic capsule biopsy will be measured using digital image software. Four (4) thickness measurements will be performed across the image for each biopsy sample, and the average fibrotic thickness will be reported for each sample. In addition, the total average thickness across the four samples will be determined based on the average individual recordings.	Surgical Procedure Visit
Secondary	Documented CIED Complications	Comparison between cohorts of documented clinical outcomes and complications since the most recent CIED procedure through the current change-out/revision procedure. Assessment of the clinical outcomes & events of the 3 cohorts will inform on potential differences in clinical outcomes that may be related to the cohort treatment. For example: infection, Twiddler's syndrome, CIED migration, CIED erosion, lead revision, lead dislodgement, pocket revision, device reprogramming, pocket revision.	Pre-Surgery Visit

External Links

•   Aziyo Biologics, Inc.